Advanced Filters
noise

Lund, Sweden Clinical Trials

A listing of Lund, Sweden clinical trials actively recruiting patients volunteers.

Found 208 clinical trials

A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global …

18 - 65 years of age Both Phase 2/3
L Lotta Cinthio

VITALYST Early Feasibility Study in High-Risk PCI Patients (VITALYST EFS)

The VITALYST Early Feasibility study (EFS) is designed to evaluate the feasibility and safety of the VITALYST System in subjects undergoing elective high-risk percutaneous coronary intervention (HR-PCI).

18 - 89 years of age Both Phase N/A

A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients

The purpose of this study is to investigate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TCD601 (siplizumab) in newly diagnosed adult ALS patients.

18 - 80 years of age Both Phase 1
E Elin Östman

The Effects of Fermented Brown Seaweed Intake on Glucose Metabolism and Gut Health

The aim of this randomised, controlled, cross-over study is to investigate whether the intake of fermented brown seaweed can lower postprandial blood glucose levels and influence the composition of the gut microbiota in 25 healthy volunteers. Well-being and gastrointestinal symptoms as well as sensory properties of the products will also …

20 - 40 years of age Both Phase N/A
M Mattias Olin, MD

Photon Therapy Versus Proton Therapy in Early Tonsil Cancer.

In this trial, patients with early squamous cell carcinoma of the tonsil with clinical stage T1-2 (p16-positive or p16-negative) N0-1 (p16-positive)/N0-N2b (p16-negative) according to American Joint Committee on Cancer (AJCC) 8th edition, aimed for unimodal and ipsilateral treatment with radiotherapy with curative intent will be included. The patients will be …

18 - 100 years of age Both Phase N/A

Ixekizumab Diabetes Intervention Trial (I-DIT)

Although the clinical onset of type 1 diabetes (T1D) is acute, the progression of T1D occurs over many years often in a patchy manner with inflammation in certain lobes of the pancreas, leaving other lobes unaffected and long-lasting beta cells remain functional decades after diagnosis. Psoriasis share several aspects with …

18 - 35 years of age Both Phase 2
P Per Bore, Masters

Psychological Therapy for Gaming Disorder

Gaming is a common leisure activity, both for children and adult, and while it is generally a positive experience for most, it can lead to problems for some individuals. There is currently a lack of knowledge of when video gaming becomes a problem and why, and there is a lack …

13 - 100 years of age Both Phase N/A
A Anders Joelson, MD, PhD

StUdy oN Burst Fractures (SunBurst)

Thoracolumbar (TL) burst fractures are seen in all ages and usually associated with high-energy trauma. Treatment include both surgical and non-surgical options. In cases without neurological deficit or definite rupture of the posterior ligament complex (PLC) both surgical treatment and non-surgical treatment are considered standard of care. This study aims …

18 - 66 years of age Both Phase N/A
A Alexander Henze, MD

Swedish Trial on Embolization of Middle Meningeal Artery Versus Surgical Evacuation in Chronic Subdural Hematoma

The SWEMMA trial is an open, national, multi-center, prospective, randomized (1:1), superiority trial designed to assess impact on reoperation rates for chronic subdural hematoma with a head-to-head comparison of embolization of the middle meningeal artery (intervention) with standard neurosurgical hematoma evacuation (control).

18 - 89 years of age Both Phase N/A

Phase Ib/IIa Trial With AC01 in Patients With HFrEF

This is a randomized, double-blind, placebo-controlled two-part study with a multiple escalating dose phase followed by a cohort expansion phase to assess safety, tolerability, pharmacokinetics and pharmacodynamics of AC01 in patients with heart failure with reduced ejection fraction (HFrEF).

18 - 80 years of age Both Phase 1/2

Rewrite in simple language using AI